Stay updated on Psilocybin Effects on MDD: Clinical Trial
Sign up to get notified when there's something new on the Psilocybin Effects on MDD: Clinical Trial page.

Latest updates to the Psilocybin Effects on MDD: Clinical Trial page
- Check5 days agoChange DetectedThe page now displays the completed PSIPET Phase 2 study record, describing a randomized trial of psilocybin versus niacin for major depressive disorder. It includes participant criteria, outcome measures, study dates, collaborators, and a related publication.SummaryDifference46%

- Check12 days agoChange DetectedThe site footer revision label changed from v3.7.2 to v3.8.0. The study record continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check19 days agoChange DetectedAn NIH banner announces updates and FAQs about the agency’s transition from using “Artificial Intelligence” to “Super Intelligence” terminology.SummaryDifference1%

- Check26 days agoChange DetectedThe site footer revision label changes from v3.7.1 to v3.7.2, while the page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check33 days agoChange DetectedThe footer revision label changes from v3.7.0 to v3.7.1 on the page displaying a 403 Forbidden error.SummaryDifference0.2%

- Check54 days agoChange DetectedThe page now displays a 403 Forbidden error instead of the study record content. The layout shows a simple error page with a Home link and site footer, indicating restricted access to the trial details.SummaryDifference18%

Stay in the know with updates to Psilocybin Effects on MDD: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Psilocybin Effects on MDD: Clinical Trial page.